Low-Cost Genetic Test Can Distinguish Bacterial from Viral Infections
|
By LabMedica International staff writers Posted on 19 Jul 2016 |

Image: The breakthrough 7-gene blood test may enable physicians to determine whether their patients have a bacterial or viral infection (Photo courtesy of Erin Kunkel and Stanford University Medical Center).
Upon identifying a set of seven relevant genes, a breakthrough rapid blood test has been developed that, with further development and testing, may soon enable physicians to determine if a patient has a bacterial or viral infection.
Too often there’s no easy way to diagnose whether a patient’s illness is bacterial or viral or if there is any infection at all. “A lot of times you can’t really tell what kind of infection someone has,” said lead author Timothy Sweeney, MD, PhD, engineering research associate, Stanford, “If someone comes into the clinic, a bacterial or a viral infection often look exactly the same.”
“The idea to look for a diagnostic test came from our previous paper in Immunity last year,” said senior author and team leader Purvesh Khatri, PhD, assistant professor, Stanford University Medical Center (Stanford, CA, USA), “In that paper, we found a common response by the human immune system to multiple viruses that is distinct from that for bacterial infections. We wondered whether we could exploit that difference to improve the diagnosis of bacterial or viral infections. But we needed a gene signature consisting of far fewer genes for the test to be clinically useful.”
The team used publicly available patient gene expression data to pinpoint 7 genes whose activity changes during an infection such that their pattern of activity can distinguish whether an infection is bacterial or viral. The 7-gene test is a vast improvement over earlier tests that look at the activity of 100s of genes. Because so few genes are involved, the new test will be cheaper and faster, while remaining accurate.
A study in Nepal co-authored by assistant professor Jason Andrews, MD, revealed that only 5% of patients who received antibiotics actually needed them, said Prof. Khatri. The Nepalese patients got antibiotic treatment because the drug was cheaper than trying to figure out if they actually needed it. “If we really want to make a difference,” Prof. Khatri said, “our test has to be more cost-effective than the drug itself.” That’s an important breakpoint.
The work is part of a global response to the need to reduce the use of antibiotics, driven in part by President Obama’s National Action Plan for Combating Antibiotic-Resistant Bacteria. Besides promoting evolution of drug-resistant microbes, antibiotics increase the risk of side effects such as tendon rupture or kidney damage, and can damage gut and other microbiomes essential to overall health.
The new test for bacterial infection faces two main hurdles before it can be made clinically available. First, it must be thoroughly tested in a clinical setting. Until now, the data and test results for this ongoing work have all come from preexisting, online digital data sets of gene expression from patients with different kinds of infections — not from current patients. The new study tested the 7-gene test on blood samples from 96 critically ill children, using a NanoString assay, and found that the test was accurate. This is a proof-of-concept but needs to be further validated in larger numbers of patients.
Second, the test needs to be incorporated into a device that can give a result in up to 1 hour. The preliminary NanoString version of the blood test takes 4-6 hours, rapid but too long for critically ill patients who, for example, have sepsis. So the researchers are working on a way to engineer the test to provide results in under an hour. The plan is to combine an 11-gene test (that they recently created a few months ago) with the newer 7-gene test. The 11-gene test reveals if the patient has an infection at all. If they do have an infection, the 7-gene test reveals if it is bacterial or viral. Both tests would be run simultaneously.
The researchers envision the two tests as a decision tree. “When you put the new 7-gene set together with the 11-gene set, we can make a decision tree that matches how a physician might think about a patient,” said Dr. Sweeney, “First we ask, ‘Is an infection present?’ Because some people present with an inflammation, a fever, a high heart rate, but it’s not due to an infection. Then we ask, ‘If so, what kind?’”
The study, by Sweeney TE et al, was published July 6, 2016, in the journal Science Translational Medicine.
Related Links:
Stanford University Medical Center
Too often there’s no easy way to diagnose whether a patient’s illness is bacterial or viral or if there is any infection at all. “A lot of times you can’t really tell what kind of infection someone has,” said lead author Timothy Sweeney, MD, PhD, engineering research associate, Stanford, “If someone comes into the clinic, a bacterial or a viral infection often look exactly the same.”
“The idea to look for a diagnostic test came from our previous paper in Immunity last year,” said senior author and team leader Purvesh Khatri, PhD, assistant professor, Stanford University Medical Center (Stanford, CA, USA), “In that paper, we found a common response by the human immune system to multiple viruses that is distinct from that for bacterial infections. We wondered whether we could exploit that difference to improve the diagnosis of bacterial or viral infections. But we needed a gene signature consisting of far fewer genes for the test to be clinically useful.”
The team used publicly available patient gene expression data to pinpoint 7 genes whose activity changes during an infection such that their pattern of activity can distinguish whether an infection is bacterial or viral. The 7-gene test is a vast improvement over earlier tests that look at the activity of 100s of genes. Because so few genes are involved, the new test will be cheaper and faster, while remaining accurate.
A study in Nepal co-authored by assistant professor Jason Andrews, MD, revealed that only 5% of patients who received antibiotics actually needed them, said Prof. Khatri. The Nepalese patients got antibiotic treatment because the drug was cheaper than trying to figure out if they actually needed it. “If we really want to make a difference,” Prof. Khatri said, “our test has to be more cost-effective than the drug itself.” That’s an important breakpoint.
The work is part of a global response to the need to reduce the use of antibiotics, driven in part by President Obama’s National Action Plan for Combating Antibiotic-Resistant Bacteria. Besides promoting evolution of drug-resistant microbes, antibiotics increase the risk of side effects such as tendon rupture or kidney damage, and can damage gut and other microbiomes essential to overall health.
The new test for bacterial infection faces two main hurdles before it can be made clinically available. First, it must be thoroughly tested in a clinical setting. Until now, the data and test results for this ongoing work have all come from preexisting, online digital data sets of gene expression from patients with different kinds of infections — not from current patients. The new study tested the 7-gene test on blood samples from 96 critically ill children, using a NanoString assay, and found that the test was accurate. This is a proof-of-concept but needs to be further validated in larger numbers of patients.
Second, the test needs to be incorporated into a device that can give a result in up to 1 hour. The preliminary NanoString version of the blood test takes 4-6 hours, rapid but too long for critically ill patients who, for example, have sepsis. So the researchers are working on a way to engineer the test to provide results in under an hour. The plan is to combine an 11-gene test (that they recently created a few months ago) with the newer 7-gene test. The 11-gene test reveals if the patient has an infection at all. If they do have an infection, the 7-gene test reveals if it is bacterial or viral. Both tests would be run simultaneously.
The researchers envision the two tests as a decision tree. “When you put the new 7-gene set together with the 11-gene set, we can make a decision tree that matches how a physician might think about a patient,” said Dr. Sweeney, “First we ask, ‘Is an infection present?’ Because some people present with an inflammation, a fever, a high heart rate, but it’s not due to an infection. Then we ask, ‘If so, what kind?’”
The study, by Sweeney TE et al, was published July 6, 2016, in the journal Science Translational Medicine.
Related Links:
Stanford University Medical Center
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







